InMed Pharmaceuticals (OTCQB: IMLFF) was recently featured in a Forbes article highlighting the company’s cannabinoid manufacturing system and database, which is used to map different compounds of cannabinoids to the various diseases they are able to treat. According to the article, InMed’s database appeals to other biotech companies who are now willing to purchase the information. Using its database, InMed has been able to identify two new cannabinoid therapies. Additionally, the company has created a method of biosynthesis for cannabinoids that is comparable to the system used to create synthetic insulin for diabetic patients. The company begins with the cannabinoid DNA and puts it into E-coli. The E-coli DNA is then removed, causing the cannabinoid DNA to take over. The process is expected to be available for labs by the fall of 2017.
To view the full article, visit: http://nnw.fm/uq9YM
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CBDWire (CBDW). NNB keeps you up-to-date on active US Public Companies complementary to CBDW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Please see full disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer